(Q38471121)

English

Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials

scientific article published on 23 May 2012

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

ulcerative colitis

1 reference

based on heuristic

inferred from title

author name string

G R Lichtenstein

1

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

S Zakko

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

G L Gordon

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

U Murthy

4

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

S Sedghi

5

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

R Pruitt

6

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

K Merchant

7

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

E Bortey

8

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

W P Forbes

9

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

language of work or name

0 references

publication date

23 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

36

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

126-134

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05142.X

21 January 2018

A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05142.X

21 January 2018

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05142.X

21 January 2018

Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05142.X

21 January 2018

Systematic review: adherence issues in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05142.X

21 January 2018

Medication non-adherence is associated with increased medical health care costs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05142.X

21 January 2018

Interventions to enhance medication adherence in chronic medical conditions: a systematic review.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05142.X

21 January 2018

Clinical trial: once‐daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6‐month placebo‐controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05142.X

21 January 2018

The continuing unethical use of placebo controls

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05142.X

21 January 2018

Placebo-controlled trials and the Declaration of Helsinki

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05142.X

21 January 2018

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05142.X

21 January 2018

Placebos in clinical practice and research

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05142.X

21 January 2018

Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05142.X

21 January 2018

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05142.X

21 January 2018

Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05142.X

21 January 2018

Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05142.X

21 January 2018

Identifiers

10.1111/J.1365-2036.2012.05142.X

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38471121&oldid=1761298443"